Payment overview · 2025
General Payments
$33.19
2 reported records · 2 companies
Healthcare provider profile · identity verified
Robert B Hall, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MOULTON, AL · NPI 1588724058
Verified facts
What the public records show
CMS Open Payments records show Robert B Hall, M.D. received $33.19 in general payments during 2025 across 2 reported records.
Novo Nordisk Inc accounted for 53.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
A separate comparison found the same explicitly named product in public Medicare Part D data: Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Vraylar by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.58 | 53.0% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $15.61 | 47.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $33.19 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $15.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 694 | 139 |
| Metoprolol Succinate | Metoprolol Succinate | 424 | 87 |
| Omeprazole | Omeprazole | 396 | 85 |
| Atorvastatin Calcium | Atorvastatin Calcium | 393 | 92 |
| Levothyroxine Sodium | Levothyroxine Sodium | 369 | 65 |
| Gabapentin | Gabapentin | 287 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 270 | 44 |
| Tramadol Hcl | Tramadol Hcl | 249 | 51 |
| Meloxicam | Meloxicam | 237 | 52 |
| Clonazepam | Clonazepam | 227 | 29 |
| Lisinopril | Lisinopril | 226 | 55 |
| Metformin Hcl Er | Metformin Hcl | 206 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 196 | 42 |
| Celecoxib | Celecoxib | 181 | 40 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 175 | 42 |
| Furosemide | Furosemide | 165 | 40 |
| Citalopram Hbr | Citalopram Hydrobromide | 164 | 28 |
| Alprazolam | Alprazolam | 163 | 19 |
| Sertraline Hcl | Sertraline Hcl | 161 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 151 | 41 |
| Zolpidem Tartrate | Zolpidem Tartrate | 144 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 140 | 37 |
| Temazepam | Temazepam | 133 | 19 |
| Montelukast Sodium | Montelukast Sodium | 131 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 128 | 21 |
| Prednisone | Prednisone | 124 | 66 |
| Potassium Chloride | Potassium Chloride | 112 | 24 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 107 | 27 |
| Trazodone Hcl | Trazodone Hcl | 106 | 23 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 102 | 37 |
| Azithromycin | Azithromycin | 99 | 69 |
| Eliquis | Apixaban | 98 | 13 |
| Cefdinir | Cefdinir | 97 | 72 |
| Donepezil Hcl | Donepezil Hcl | 97 | 17 |
| Allopurinol | Allopurinol | 96 | 19 |
| Glipizide Er | Glipizide | 96 | 22 |
| Carvedilol | Carvedilol | 95 | 17 |
| Clopidogrel | Clopidogrel Bisulfate | 92 | 21 |
| Ondansetron Hcl | Ondansetron Hcl | 92 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 91 | 15 |
| Bupropion Hcl Sr | Bupropion Hcl | 90 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 88 | 14 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 87 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 83 | 13 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 81 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 78 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 78 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 76 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 76 | 17 |
| Famotidine | Famotidine | 73 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 72 | 15 |
| Simvastatin | Simvastatin | 70 | 18 |
| Ezetimibe | Ezetimibe | 68 | 12 |
| Losartan Potassium | Losartan Potassium | 64 | 20 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 62 | 12 |
| Methocarbamol | Methocarbamol | 59 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 59 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 58 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 58 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 57 | 16 |
| Metformin Hcl | Metformin Hcl | 57 | 11 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 57 | 12 |
| Pregabalin | Pregabalin | 56 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Cephalexin | Cephalexin | 53 | 38 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 52 | 15 |
| Buspirone Hcl | Buspirone Hcl | 51 | suppressed |
| Estradiol | Estradiol | 49 | suppressed |
| Naproxen | Naproxen | 45 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 40 |
| Jardiance | Empagliflozin | 44 | suppressed |
| Lansoprazole | Lansoprazole | 44 | suppressed |
| Lorazepam | Lorazepam | 44 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 43 | suppressed |
| Fluconazole | Fluconazole | 42 | 17 |
| Atenolol | Atenolol | 41 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 41 | suppressed |
| Levetiracetam | Levetiracetam | 41 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 41 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 40 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 37 | suppressed |
| Sucralfate | Sucralfate | 36 | 11 |
| Azelastine Hcl | Azelastine Hcl | 34 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 27 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | suppressed |
| Primidone | Primidone | 31 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 29 | 15 |
| Linzess | Linaclotide | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Eszopiclone | Eszopiclone | 27 | suppressed |
| Methylprednisolone | Methylprednisolone | 27 | 18 |
| Topiramate | Topiramate | 24 | suppressed |
| Glimepiride | Glimepiride | 23 | suppressed |
| Risperidone | Risperidone | 23 | suppressed |
| Torsemide | Torsemide | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 13 |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 22 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Ozempic | Semaglutide | 20 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 20 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 19 | suppressed |
| Digoxin | Digoxin | 19 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 18 |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 19 | suppressed |
| Levofloxacin | Levofloxacin | 18 | 14 |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Nystatin | Nystatin | 16 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 15 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 14 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 14 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 14 | suppressed |
| Vraylar | Cariprazine Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 13 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Lacosamide | Lacosamide | 12 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 12 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Fluocinonide | Fluocinonide | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $33.19 · 2 records | Novo Nordisk Inc | VRAYLAR | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Vraylar play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error